Specific Inhibition of HIF Activity: Can Peptides Lead the Way?
Open accessThe DOI matches its Crossref record; 136 of the 140 references it cites were found in a registry or an index.
Abstract
Reduced oxygen availability (hypoxia) is a characteristic of many disorders including cancer. Central components of the systemic and cellular response to hypoxia are the Hypoxia Inducible Factors (HIFs), a small family of heterodimeric transcription factors that directly or indirectly regulate the expression of hundreds of genes, the products of which mediate adaptive changes in processes that include metabolism, erythropoiesis, and angiogenesis. The overexpression of HIFs has been linked to the pathogenesis and progression of cancer. Moreover, evidence from cellular and animal models have convincingly shown that targeting HIFs represents a valid approach to treat hypoxia-related disorders. However, targeting transcription factors with small molecules is a very demanding task and development of HIF inhibitors with specificity and therapeutic potential has largely remained an unattainable challenge. Another promising approach to inhibit HIFs is to use peptides modelled after HIF subunit domains known to be involved in protein–protein interactions that are critical for HIF function. Introduction of these peptides into cells can inhibit, through competition, the activity of endogenous HIFs in a sequence and, therefore also isoform, specific manner. This review summarizes the involvement of HIFs in cancer and the approaches for targeting them, with a special focus on the development of peptide HIF inhibitors and their prospects as highly-specific pharmacological agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike HIF-2α, no pharmacological agents that specifically target HIF-1α have been described, although a number of compounds which target HIF-1α mRNA expression, protein synthesis/stabilization and dimerization, have been identified [110].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [110]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451 · cited 2×
“For example, acriflavine (an antibacterial drug) can bind to the PAS-B domain of both HIFα subunits, which share significant homology in this part [98].”
BackgroundRetractedLee, K., Qian, D. Z., Rey, S., Wei, H., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812801106 · Cited by 289
RetractedWang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212 · cited 2×
“Heterodimerization and DNA binding are mediated by the Per-Arnt-Sim (PAS) homology and basic helix-loop-helix (bHLH) domains, respectively, which are present at the N-terminal parts of all HIF subunits [18].”
BackgroundJaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Semenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166 · cited 1×
“HIFs and especially HIF-1 influence several hallmarks of cancer such as genomic instability, tumor cell invasion, metastasis, and angiogenesis as well as suppression of the anti-tumor immune response [5,63].”
BackgroundPurification and Characterization of Hypoxia-inducible Factor 1
Wang, G. L., & Semenza, G. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1230 · Cited by 2,073
Therapeutic peptides: Historical perspectives, current development trends, and future directions
Lau, J. L., & Dunn, M. K. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.052 · Cited by 1,879
HIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712 · cited 1×
“, VHL loss of function in renal carcinoma) [86].”
BackgroundNF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α
Rius, J., Guma, M., Schachtrup, C., Akassoglou, K., Zinkernagel, A. S., Nizet, V., Johnson, R. S., Haddad, G. G., & Karin, M. (2008) · Nature · doi:10.1038/nature06905 · Cited by 1,614
Lando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., & Bruick, R. K. (2002) · Genes & Development · doi:10.1101/gad.991402 · Cited by 1,550 · cited 1×
“A second oxygen dependent hydroxylation occurs at an asparagine residue in the C-TAD of HIFα and is catalyzed by a different oxygenase, called FIH (Factor Inhibiting HIF) [29,30].”
BackgroundGeneral involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.
Wang, G. L., & Semenza, G. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.9.4304 · Cited by 1,468
(2000) · PubMed · Cited by 1,445
Mahon, P. C., Hirota, K., & Semenza, G. L. (2001) · Genes & Development · doi:10.1101/gad.924501 · Cited by 1,385
Tian, H., McKnight, S. L., & Russell, D. W. (1997) · Genes & Development · doi:10.1101/gad.11.1.72 · Cited by 1,351 · cited 1×
“Unlike HIF-1α that can be expressed in all types of cells, HIF-2α, encoded by the EPAS1 gene, is expressed in a few tissues such as placenta, lungs, liver, and heart, and holds a central role in angiogenesis and erythropoiesis [12,13].”
BackgroundBerra, E., Benizri, E., Ginouvès, A., Volmat, V., Roux, D., & Pouysségur, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg392 · Cited by 1,348
Direct regulation of TWIST by HIF-1α promotes metastasis
Yang, M.-H., Wu, M.-Z., Chiou, S.-H., Chen, P.-M., Chang, S.-Y., Liu, C.-J., Teng, S.-C., & Wu, K.-J. (2008) · Nature Cell Biology · doi:10.1038/ncb1691 · Cited by 1,345 · cited 1×
“HIFs facilitate EMT mainly by enhancing the expression of genes such as TCF3, ZFHX1A/B, and TWIST, which repress E-cadherin and epithelial type promoting factors, while, at the same time, the expression of mesenchymal type genes is increased [73,74].”
BackgroundLaughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256 · cited 1×
“As an example, heregulin (a member of the EGF family of growth factors) induces HIF-1 by activating the PI3K/Akt/mTOR pathway and increasing the rate of HIF-1α translation [55].”
BackgroundERK signalling: A master regulator of cell behaviour, life and fate
Lavoie, H., Gagnon, J., & Therrien, M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0255-7 · Cited by 1,185
Tumour acidosis: from the passenger to the driver's seat
Corbet, C., & Feron, O. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.77 · Cited by 988 · cited 1×
“, stromal cells), which are known to play an important role for cancer development [64,68].”
BackgroundHypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962 · cited 5×
“As already discussed, HIF activation facilitates cancer progression and has been correlated with increased patient mortality [5].”
BackgroundInfluential(2002) · PubMed · Cited by 840
Transcriptional regulation by hypoxia inducible factors
Dengler, V. L., Galbraith, M. D., & Espinosa, J. M. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.838205 · Cited by 782 · cited 4×
“Most importantly, HIF-1 holds a prominent role as mediator of the metabolic reprogramming that characterizes many types of cancer cells [8,64].”
BackgroundInfluentialPelay‐Gimeno, M., Glas, A., Koch, O., & Grossmann, T. N. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201412070 · Cited by 717
Targeting renal cell carcinoma with a HIF-2 antagonist
Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature · doi:10.1038/nature19796 · Cited by 709 · cited 2×
“More importantly, these compounds (PT2399, and PT2385) were efficient inhibitors of HIF-2 activity, exhibited anticancer properties in both cellular and animal renal carcinoma models and PT2385 administration to a patient with metastatic renal carcinoma (ccRCC) showed very promising results [99,114].”
BackgroundInhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression
Makino, Y., Cao, R., Svensson, K., Bertilsson, G., Asman, M., Tanaka, H., Cao, Y., Berkenstam, A., & Poellinger, L. (2001) · Nature · doi:10.1038/35107085 · Cited by 705 · cited 5×
“The feasibility of inhibiting HIF heterodimerization using peptides stems from early studies which demonstrated that shorter splice variants of HIF-3α (IPAS) are expressed in human and mouse tissues and downregulate HIF activity [15,120].”
BackgroundInfluentialA Comprehensive Review on Current Advances in Peptide Drug Development and Design
Lee, A. C.-L., Harris, J. L., Khanna, K. K., & Hong, J.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102383 · Cited by 686
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality
Jonasch, E., Walker, C. L., & Rathmell, W. K. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00359-2 · Cited by 644 · cited 1×
“Even when HIFα is constitutively activated due to pVHL function loss in renal cells, development of renal carcinoma requires additional mutations [84].”
BackgroundDigoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624 · cited 1×
“, digoxin) [91], topoisomerase inhibitors (e.”
HIF-Dependent Antitumorigenic Effect of Antioxidants In Vivo
Gao, P., Zhang, H., Dinavahi, R., Li, F., Xiang, Y., Raman, V., Bhujwalla, Z. M., Felsher, D. W., Cheng, L., Pevsner, J., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.004 · Cited by 523 · cited 1×
“, N-acetyl cysteine) that destabilize HIFα subunits in a PHD/VHL-mediated manner [97].”
BackgroundEchinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1235 · Cited by 508
Suppression of tumor growth through disruption of hypoxia-inducible transcription
Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G., & Livingston, D. M. (2000) · Nature Medicine · doi:10.1038/82146 · Cited by 501
Richard, D. E., Berra, E., & Pouysségur, J. (2000) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)61441-9 · Cited by 488
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.009 · Cited by 480
Liu, Y. V., Baek, J. H., Zhang, H., Diez, R., Cole, R. N., & Semenza, G. L. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.01.001 · Cited by 478
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
Cho, H., Du, X., Rizzi, J. P., Liberzon, E., Chakraborty, A. A., Gao, W., Carvo, I., Signoretti, S., Bruick, R. K., Josey, J. A., et al. (2016) · Nature · doi:10.1038/nature19795 · Cited by 451
Oxygen availability and metabolic adaptations
Nakazawa, M. S., Keith, B., & Simon, M. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.84 · Cited by 435 · cited 3×
“, stromal cells), which are known to play an important role for cancer development [64,68].”
BackgroundGörlach, A., Diebold, I., Schini-Kerth, V. B., Berchner-Pfannschmidt, U., Roth, U., Brandes, R. P., Kietzmann, T., & Busse, R. (2001) · Circulation Research · doi:10.1161/hh1301.092678 · Cited by 416
Krishnamachary, B., Zagzag, D., Nagasawa, H., Rainey, K., Okuyama, H., Baek, J. H., & Semenza, G. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3719 · Cited by 415 · cited 1×
“HIFs facilitate EMT mainly by enhancing the expression of genes such as TCF3, ZFHX1A/B, and TWIST, which repress E-cadherin and epithelial type promoting factors, while, at the same time, the expression of mesenchymal type genes is increased [73,74].”
BackgroundCourtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2627 · Cited by 393
New Modalities for Challenging Targets in Drug Discovery
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 382
Cyclic Peptides as Therapeutic Agents and Biochemical Tools
Joo, S.-H. (2012) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2012.20.1.019 · Cited by 359
Hu, C.-J., Sataur, A., Wang, L., Chen, H., & Simon, M. C. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-05-0419 · Cited by 355 · cited 2×
“Domainswapping experiments have suggested that HIF target gene specificity may be conferred by the N-TAD through its interaction with additional transcriptional co-regulators [22].”
BackgroundThe transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy
Albadari, N., Deng, S., & Li, W. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1613370 · Cited by 351 · cited 3×
“Considering the pivotal role of HIFs and hypoxia in cancer, it is of no surprise that HIFs have been long targeted as means of anti-cancer therapy [6,7].”
BackgroundStructural integration in hypoxia-inducible factors
Wu, D., Potluri, N., Lu, J., Kim, Y., & Rastinejad, F. (2015) · Nature · doi:10.1038/nature14883 · Cited by 346 · cited 15×
“The α-helices of their bHLH domains associate with the major groove of the recognition motif and their PAS-A domains cooperate with the bHLH domains of the heterodimer to establish binding to DNA [19].”
BackgroundInfluentialGordon, M. S. (2007) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)70352-x · Cited by 346
Hypoxia-inducible factors and the regulation of lipid metabolism
Mylonis, I., Simos, G., & Paraskeva, E. (2019) · Cells · doi:10.3390/cells8030214 · Cited by 316
Self-citationMechanisms of hypoxia signalling: new implications for nephrology
Schödel, J., & Ratcliffe, P. J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0182-z · Cited by 309 · cited 1×
“Under hypoxia, low O2 levels as well as the production of ROS by oxygen-starving mitochondria inhibit hydroxylation and HIFαs escape degradation, accumulate, and translocate inside the nucleus where they assemble with ARNT into transcriptionally active heterodimers (Figure 1) [31].”
BackgroundArtificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor
Scheuermann, T. H., Tomchick, D. R., Machius, M., Guo, Y., Bruick, R. K., & Gardner, K. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808092106 · Cited by 301
(2002) · PubMed · Cited by 296
Pharmacologic Targeting of Hypoxia-Inducible Factors
Semenza, G. L. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021637 · Cited by 288 · cited 2×
“Considering the pivotal role of HIFs and hypoxia in cancer, it is of no surprise that HIFs have been long targeted as means of anti-cancer therapy [6,7].”
BackgroundStiehl, D. P., Jelkmann, W., Wenger, R. H., & Hellwig-Bürgel, T. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02247-0 · Cited by 285
Hara, S., Hamada, J., Kobayashi, C., Kondo, Y., & Imura, N. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5659 · Cited by 282
Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies
Habault, J., & Poyet, J.-L. (2019) · Molecules · doi:10.3390/molecules24050927 · Cited by 280
Mylonis, I., Chachami, G., Samiotaki, M., Panayotou, G., Paraskeva, E., Kalousi, A., Georgatsou, E., Bonanou, S., & Simos, G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605058200 · Cited by 266 · cited 4×
“Other chemicals such as PD98059 and U0126 or naturally occurring substances such as Kaempferol that inhibit the activation of ERK1/2 pathway, impair the phosphorylation of both HIFα subunits, and thus promote CRM1-dependent nuclear export of HIFα, subsequent impeding HIF transcriptional activity and proliferation of c…”
BackgroundInfluentialSelf-citationRan, X., & Gestwicki, J. E. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.06.004 · Cited by 263
Chaperone-mediated Autophagy Targets Hypoxia-inducible Factor-1α (HIF-1α) for Lysosomal Degradation
Hubbi, M. E., Hu, H., Kshitiz, Ahmed, I., Levchenko, A., & Semenza, G. L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.414771 · Cited by 242
Hypoxia: Signaling the Metastatic Cascade
Rankin, E. B., Nam, J.-M., & Giaccia, A. J. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.05.006 · Cited by 239 · cited 1×
“In addition, the high oxygen consumption rates of the rapidly proliferating cancer cell intensify the formation of hypoxic niches within solid tumors [3].”
BackgroundTherapeutic applications of the cell-penetrating HIV-1 Tat peptide
Rizzuti, M., Nizzardo, M., Zanetta, C., Ramirez, A., & Corti, S. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.017 · Cited by 224
Roles of the human hypoxia-inducible factor (HIF)-3α variants in the hypoxia response
Heikkilä, M., Pasanen, A., Kivirikko, K. I., & Myllyharju, J. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0679-5 · Cited by 213 · cited 1×
“HIF-3α, the less studied isoform, has many spliced variants with distinct expression pattern [14] and diverging functionalities ranging from HIF-1 inhibition to transcriptional activation of HIF targets [15,16].”
Background(2000) · PubMed · Cited by 206
Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes
Skuli, N., Majmundar, A. J., Krock, B. L., Mesquita, R. C., Mathew, L. K., Quinn, Z. L., Runge, A., Liu, L., Kim, M. N., Liang, J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57322 · Cited by 200
A complex task? Direct modulation of transcription factors with small molecules
Koehler, A. N. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.022 · Cited by 189 · cited 1×
“Transcription factors such as HIFs have been long considered undruggable because they do not contain a single targetable catalytic site (as enzymes do) but their activity relies on protein–DNA or protein–protein interactions, specific inhibition of which by small molecules is very challenging [87], especially when no…”
BackgroundRapisarda, A., Zalek, J., Hollingshead, M., Braunschweig, T., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Hewitt, S. M., Shoemaker, R. H., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2116 · Cited by 187 · cited 1×
“, topotecan) [92], agents that target components of the mTOR pathway (e.”
BackgroundMiranda, E., Nordgren, I. K., Male, A. L., Lawrence, C. E., Hoakwie, F., Cuda, F., Court, W., Fox, K. R., Townsend, P. A., Packham, G. K., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja402993u · Cited by 185
Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience
Sanghani, N. S., & Haase, V. H. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.04.004 · Cited by 185 · cited 1×
“These issues have become especially important due the recent licensing and wide clinical administration of PHD inhibitors as HIF activators, and subsequent erythropoiesis inducers, for the treatment of patients suffering from renal anemia [85].”
BackgroundNew horizons in hypoxia signaling pathways
Pugh, C. W., & Ratcliffe, P. J. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.03.008 · Cited by 184 · cited 1×
“Detailed studies have shown that HIF-1α, as well as the other HIFα forms, are stabilized under hypoxia by an oxygen dependent mechanism (Figure 1) [17].”
BackgroundDepping, R., Steinhoff, A., Schindler, S., Friedrich, B., Fagerlund, R., Metzen, E., Hartmann, E., & Köhler, M. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.12.006 · Cited by 179 · cited 1×
“More specifically, while import of HIF-1α inside the nucleus is constitutive, mediated by the importin α/β as well as importins 4/7 [40,41], nuclear export of HIF-1α is regulated in an ERK1/2- and CRM1dependent manner (Figure 1) [38,39].”
BackgroundKietzmann, T., Mennerich, D., & Dimova, E. Y. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00011 · Cited by 176 · cited 1×
“Both HIF-1α and HIF-2α can be directly phosphorylated by several kinases including GSK3, PLK3, ATM, PKA, CDK1, and the extent of their modification depends on cell type and extracellular signals [34,35].”
BackgroundChen, J., Zhao, S., Nakada, K., Kuge, Y., Tamaki, N., Okada, F., Wang, J., Shindo, M., Higashino, F., Takeda, K., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63924-7 · Cited by 170
Mechanisms and Consequences of Oxygen and Carbon Dioxide Sensing in Mammals
Cummins, E. P., Strowitzki, M. J., & Taylor, C. T. (2019) · Physiological Reviews · doi:10.1152/physrev.00003.2019 · Cited by 153 · cited 1×
“Despite the unequivocal involvement of HIFs in the adaptation of cancer cells in the hypoxic tumor microenvironment, which promotes tumor progression, metastasis and resistance to therapy, it is still questionable whether HIFs by themselves are pro-oncogenic in a normal genetic background [83].”
BackgroundMutant V600E BRAF Increases Hypoxia Inducible Factor-1α Expression in Melanoma
Kumar, S. M., Yu, H., Edwards, R., Chen, L., Kazianis, S., Brafford, P., Acs, G., Herlyn, M., & Xu, X. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3312 · Cited by 142
The role of hypoxia‐inducible factor‐2 alpha in angiogenesis
Befani, C. D., & Liakos, P. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26805 · Cited by 139 · cited 3×
“Under hypoxia, low O2 levels as well as the production of ROS by oxygen-starving mitochondria inhibit hydroxylation and HIFαs escape degradation, accumulate, and translocate inside the nucleus where they assemble with ARNT into transcriptionally active heterodimers (Figure 1) [31].”
BackgroundOxygen‐dependent regulation of hypoxia‐inducible factors by prolyl and asparaginyl hydroxylation
Lando, D., Gorman, J. J., Whitelaw, M. L., & Peet, D. J. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03445.x · Cited by 137 · cited 2×
“The C-terminal parts of both HIF-1α and HIF-2α are also critical for function as they contain their oxygen dependent degradation domain (ODDD) as well as two distinct transactivation domains, N-TAD (overlapping with ODDD) and C-TAD (at the very C-terminus), which is responsible for the interaction between HIFα and the…”
BackgroundHypoxia causes triglyceride accumulation via HIF-1-mediated stimulation of lipin 1 expression
Mylonis, I., Sembongi, H., Befani, C., Liakos, P., Siniossoglou, S., & Simos, G. (2012) · Journal of Cell Science · doi:10.1242/jcs.106682 · Cited by 137 · cited 1×
“This often leads to accumulation of lipid droplets [37,65–67] and protects cancer cells from lipotoxicity [37,65,66].”
BackgroundSelf-citationHenchey, L. K., Kushal, S., Dubey, R., Chapman, R. N., Olenyuk, B. Z., & Arora, P. S. (2010) · Journal of the American Chemical Society · doi:10.1021/ja9082864 · Cited by 136
Albanese, A., Daly, L. A., Mennerich, D., Kietzmann, T., & Sée, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010268 · Cited by 136 · cited 2×
“Both HIF-1α and HIF-2α can be directly phosphorylated by several kinases including GSK3, PLK3, ATM, PKA, CDK1, and the extent of their modification depends on cell type and extracellular signals [34,35].”
BackgroundThe Genomics and Genetics of Oxygen Homeostasis
Semenza, G. L. (2020) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-111119-073356 · Cited by 135 · cited 2×
“At the cellular level, hypoxia triggers the stabilization of the hypoxia inducible factors (known as HIFs) [2].”
BackgroundEF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1
Thomas, S. L., Zhong, D., Zhou, W., Malik, S., Liotta, D. C., Snyder, J. P., Hamel, E., & Giannakakou, P. (2008) · Cell Cycle · doi:10.4161/cc.6410 · Cited by 127 · cited 1×
“This list also includes microtubule binding agents such as EF24 [96].”
BackgroundMylonis, I., Lakka, A., Tsakalof, A. K., & Simos, G. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.06.038 · Cited by 123
Self-citationPrinciples of Ligand Binding within a Completely Buried Cavity in HIF2α PAS-B
Key, J., Scheuermann, T. H., Anderson, P. C., Daggett, V., & Gardner, K. H. (2009) · Journal of the American Chemical Society · doi:10.1021/ja9073062 · Cited by 122 · cited 1×
“Furthermore, the PAS domains of both HIFα isoforms possess cavities, which can accommodate small ligands, but their size and distribution differs between isoforms [19,20].”
BackgroundThe ABC Transporter Abcg2/Bcrp: Role in Hypoxia Mediated Survival
Krishnamurthy, P. C., & Schuetz, J. D. (2005) · BioMetals · doi:10.1007/s10534-005-3709-7 · Cited by 120 · cited 1×
“Moreover, HIF-1 mediates chemoresistance by inducing expression of proteins that enhance drug efflux such as multidrug resistance 1 (MDR1) [76,77] and MRP2 [78] or anti-apoptotic proteins that promote drug resistance such as survivin [79,80].”
BackgroundDing, Z., Yang, L., Xie, X., Xie, F., Pan, F., Li, J., He, J., & Liang, H. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0828-5 · Cited by 116 · cited 1×
“Moreover, HIF-1 mediates chemoresistance by inducing expression of proteins that enhance drug efflux such as multidrug resistance 1 (MDR1) [76,77] and MRP2 [78] or anti-apoptotic proteins that promote drug resistance such as survivin [79,80].”
BackgroundA compendium of proteins that interact with HIF-1α
Semenza, G. L. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.03.041 · Cited by 115
Yamashita, T., Ohneda, O., Nagano, M., Iemitsu, M., Makino, Y., Tanaka, H., Miyauchi, T., Goto, K., Ohneda, K., Fujii-Kuriyama, Y., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01332-07 · Cited by 114
In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics
Lao, B. B., Grishagin, I., Mesallati, H., Brewer, T. F., Olenyuk, B. Z., & Arora, P. S. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402393111 · Cited by 112
Terzuoli, E., Puppo, M., Rapisarda, A., Uranchimeg, B., Cao, L., Burger, A. M., Ziche, M., & Melillo, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1075 · Cited by 111 · cited 1×
“These include agents such as aminoflavone shown to affect both HIF1A transcription and translation in breast cancer cell lines and xenograft models [88], GL331 that interferes with the activation of HIF1A promoter in a lung cancer cell model [89] and anthracyclines (such as idarubicin) that inhibit both HIF1A and EPAS…”
BackgroundTransport of hypoxia-inducible factor HIF-1α into the nucleus involves importins 4 and 7
Chachami, G., Paraskeva, E., Mingot, J. M., Braliou, G. G., Görlich, D., & Simos, G. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.09.093 · Cited by 104 · cited 1×
“More specifically, while import of HIF-1α inside the nucleus is constitutive, mediated by the importin α/β as well as importins 4/7 [40,41], nuclear export of HIF-1α is regulated in an ERK1/2- and CRM1dependent manner (Figure 1) [38,39].”
BackgroundSelf-citationMohlin, S., Hamidian, A., von Stedingk, K., Bridges, E., Wigerup, C., Bexell, D., & Påhlman, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0708 · Cited by 104
Peptide blockade of HIFα degradation modulates cellular metabolism and angiogenesis
Willam, C., Masson, N., Tian, Y.-M., Mahmood, S. A., Wilson, M. I., Bicknell, R., Eckardt, K.-U., Maxwell, P. H., Ratcliffe, P. J., & Pugh, C. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162119399 · Cited by 103
Protein domain mimetics as in vivo modulators of hypoxia-inducible factor signaling
Kushal, S., Lao, B. B., Henchey, L. K., Dubey, R., Mesallati, H., Traaseth, N. J., Olenyuk, B. Z., & Arora, P. S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312473110 · Cited by 98
Hypoxia and Hypoxia-Inducible Factors in Leukemias
Deynoux, M., Sunter, N. J., Hérault, O., & Mazurier, F. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00041 · Cited by 97
Mylonis, I., Chachami, G., Paraskeva, E., & Simos, G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803081200 · Cited by 96 · cited 5×
“As already mentioned, phosphorylation of Ser641/643 in the ETD domain of HIF-1α by p42/44 MAPK (ERK1/2), which are often activated in human cancers [128], is essential for HIF-1α nuclear accumulation and activity because it masks a CRM1-dependent NES [38].”
BackgroundInfluentialSelf-citationBeppu, K., Nakamura, K., Linehan, W. M., Rapisarda, A., & Thiele, C. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3332 · Cited by 96
Progress toward Overcoming Hypoxia-Induced Resistance to Solid Tumor Therapy
Reginato, M., & Karakashev, S. (2015) · Cancer Management and Research · doi:10.2147/cmar.s58285 · Cited by 95 · cited 3×
“Under hypoxia, low O2 levels as well as the production of ROS by oxygen-starving mitochondria inhibit hydroxylation and HIFαs escape degradation, accumulate, and translocate inside the nucleus where they assemble with ARNT into transcriptionally active heterodimers (Figure 1) [31].”
BackgroundCasein kinase 1 regulates human hypoxia-inducible factor HIF-1
Kalousi, A., Mylonis, I., Politou, A. S., Chachami, G., Paraskeva, E., & Simos, G. (2010) · Journal of Cell Science · doi:10.1242/jcs.068122 · Cited by 88
Self-citationOxygen‐sensing mechanisms in cells
Wilson, J. W., Shakir, D., Batie, M., Frost, M., & Rocha, S. (2020) · The FEBS Journal · doi:10.1111/febs.15374 · Cited by 86 · cited 1×
“Mammals use oxygen sensing and delivery mechanisms to match available oxygen to their tissue demands so as to fulfill their metabolic needs but also prevent toxicity caused by excess oxygen [1].”
BackgroundSEPT9_v1 Up-regulates Hypoxia-inducible Factor 1 by Preventing Its RACK1-mediated Degradation
Amir, S., Wang, R., Simons, J. W., & Mabjeesh, N. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808348200 · Cited by 80 · cited 1×
“HIF activation and regulation involves many protein–protein interactions (PPIs) [59], targeting of which may have more selective and less toxic effects.”
BackgroundCalvani, M., Trisciuoglio, D., Bergamaschi, C., Shoemaker, R. H., & Melillo, G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5564 · Cited by 80
Mylonis, I., Kourti, M., Samiotaki, M., Panayotou, G., & Simos, G. (2017) · Journal of Cell Science · doi:10.1242/jcs.195339 · Cited by 80 · cited 2×
“Other chemicals such as PD98059 and U0126 or naturally occurring substances such as Kaempferol that inhibit the activation of ERK1/2 pathway, impair the phosphorylation of both HIFα subunits, and thus promote CRM1-dependent nuclear export of HIFα, subsequent impeding HIF transcriptional activity and proliferation of c…”
BackgroundSelf-citationNoguera, R., Fredlund, E., Piqueras, M., Pietras, A., Beckman, S., Navarro, S., & Påhlman, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0223 · Cited by 78
Superoxide and derived reactive oxygen species in the regulation of hypoxia-inducible factors
Görlach, A., & Kietzmann, T. (2007) · Methods in Enzymology · doi:10.1016/s0076-6879(07)35022-2 · Cited by 73 · cited 1×
“Other exemplary modes of HIF regulation include the involvement of ROS signaling (reviewed in [56]), transcription factors such as NF-kb [57] and STAT3 [58] that upregulate transcription of the gene encoding HIF-1α and many interacting proteins such as HSP90 and RACK1, which stabilize or destabilize HIF-1α, respective…”
BackgroundEffect of hypoxia-inducible factor-1α on transcription of survivin in non-small cell lung cancer
Chen, Y.-Q., Zhao, C.-L., & Li, W. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-29 · Cited by 72 · cited 1×
“Moreover, HIF-1 mediates chemoresistance by inducing expression of proteins that enhance drug efflux such as multidrug resistance 1 (MDR1) [76,77] and MRP2 [78] or anti-apoptotic proteins that promote drug resistance such as survivin [79,80].”
BackgroundTriantafyllou, E.-A., Georgatsou, E., Mylonis, I., Simos, G., & Paraskeva, E. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.06.015 · Cited by 71
Self-citationHypoxic pathobiology of breast cancer metastasis
Schito, L., & Rey, S. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.05.004 · Cited by 68 · cited 1×
“Furthermore, HIF-mediated gene expression drives extracellular matrix remodeling, resistance to anoikis-related cell death and establishment of new cancer colonies, all of which facilitate the metastatic phenotype of hypoxic tumors [75].”
BackgroundHypercapnia Suppresses the HIF-dependent Adaptive Response to Hypoxia
Selfridge, A. C., Cavadas, M. A. S., Scholz, C. C., Campbell, E. L., Welch, L. C., Lecuona, E., Colgan, S. P., Barrett, K. E., Sporn, P. H. S., Sznajder, J. I., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.713941 · Cited by 67 · cited 1×
“HIFα stability is also affected by CO2 concentration as both in vivo and in vitro hypercapnia decrease HIFα protein levels independently of the PHD/pVHL-mediated degradation pathway and, most likely, via lysosomal proteolysis [62].”
BackgroundGL331 inhibits HIF-1α expression in a lung cancer model
Chang, H., Shyu, K., Lee, C.-C., Tsai, S.-C., Wang, B.-W., Lee, Y. H., & Lin, S. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00111-6 · Cited by 66
Tolonen, J.-P., Heikkilä, M., Malinen, M., Lee, H.-M., Palvimo, J. J., Wei, G.-H., & Myllyharju, J. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03387-9 · Cited by 63 · cited 1×
“HIF-3α, the less studied isoform, has many spliced variants with distinct expression pattern [14] and diverging functionalities ranging from HIF-1 inhibition to transcriptional activation of HIF targets [15,16].”
BackgroundKaragiota, A., Kourti, M., Simos, G., & Mylonis, I. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2985-7 · Cited by 59
Self-citationFaversani, A., Vaira, V., Moro, G. P., Tosi, D., Lopergolo, A., Schultz, D. C., Rivadeneira, D., Altieri, D. C., & Bosari, S. (2014) · Breast Cancer Research · doi:10.1186/bcr3666 · Cited by 51 · cited 1×
“Moreover, HIF-1 mediates chemoresistance by inducing expression of proteins that enhance drug efflux such as multidrug resistance 1 (MDR1) [76,77] and MRP2 [78] or anti-apoptotic proteins that promote drug resistance such as survivin [79,80].”
BackgroundHypoxia-adaptive pathways: A pharmacological target in fibrotic disease?
Strowitzki, M. J., Ritter, A. S., Kimmer, G., & Schneider, M. A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104364 · Cited by 49
HIF‐1α Expression as a Protective Strategy of HepG2 Cells Against Fatty Acid‐Induced Toxicity
Yoo, W., Noh, K. H., Ahn, J. H., Yu, J. H., Seo, J. A., Kim, S. G., Choi, K. M., Baik, S. H., Choi, D. S., Kim, T. W., et al. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24757 · Cited by 47 · cited 1×
“This often leads to accumulation of lipid droplets [37,65–67] and protects cancer cells from lipotoxicity [37,65,66].”
BackgroundKourti, M., Ikonomou, G., Giakoumakis, N.-N., Rapsomaniki, M., Landegren, U. D., Siniossoglou, S., Lygerou, Z., Simos, G., & Mylonis, I. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.02.017 · Cited by 47 · cited 1×
“This often leads to accumulation of lipid droplets [37,65–67] and protects cancer cells from lipotoxicity [37,65,66].”
BackgroundSelf-citationPapadakis, A. I., Paraskeva, E., Peidis, P., Muaddi, H., Li, S., Raptis, L., Pantopoulos, K., Simos, G., & Koromilas, A. E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0215 · Cited by 47
Self-citationIvanova, I. G., Park, C. V., & Kenneth, N. S. (2019) · Cells · doi:10.3390/cells8020114 · Cited by 44
Gkotinakou, I.-M., Befani, C., Simos, G., & Liakos, P. (2019) · Journal of Cell Science · doi:10.1242/jcs.225698 · Cited by 43 · cited 2×
“Other chemicals such as PD98059 and U0126 or naturally occurring substances such as Kaempferol that inhibit the activation of ERK1/2 pathway, impair the phosphorylation of both HIFα subunits, and thus promote CRM1-dependent nuclear export of HIFα, subsequent impeding HIF transcriptional activity and proliferation of c…”
BackgroundSelf-citationExploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologies
Kyle, H. F., Wickson, K. F., Stott, J., Burslem, G. M., Breeze, A. L., Tiede, C., Tomlinson, D. C., Warriner, S. L., Nelson, A. S., Wilson, A. J., et al. (2015) · Molecular BioSystems · doi:10.1039/c5mb00284b · Cited by 42
Wang, W., Jia, W., Xu, G., Wang, Z.-H., Li, J., Ma, J., Ge, Y., Xie, S., & Yu, J.-H. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0605-3 · Cited by 38
HIF-2α phosphorylation by CK1δ promotes erythropoietin secretion in liver cancer cells under hypoxia
Pangou, E., Befani, C., Mylonis, I., Samiotaki, M., Panayotou, G., Simos, G., & Liakos, P. (2016) · Journal of Cell Science · doi:10.1242/jcs.191395 · Cited by 37
Self-citationPang, Y., Yang, C., Schovanek, J., Wang, H., Bullova, P., Caisova, V., Gupta, G., Wolf, K. I., Semenza, G. L., Zhuang, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16224 · Cited by 37 · cited 1×
“These include agents such as aminoflavone shown to affect both HIF1A transcription and translation in breast cancer cell lines and xenograft models [88], GL331 that interferes with the activation of HIF1A promoter in a lung cancer cell model [89] and anthracyclines (such as idarubicin) that inhibit both HIF1A and EPAS…”
BackgroundHu, H., Miao, X., Li, J., Zhang, X., Xu, J., Zhang, J., Zhou, T., Hu, M.-N., Yang, W., & Mou, L. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.172961 · Cited by 37 · cited 3×
“This group includes cardiac glycosides (e.g., digoxin) [91], topoisomerase inhibitors (e.g., topotecan) [92], agents that target components of the mTOR pathway (e.g., rapamycin) [109], steroids such as calcitriol that influence HIFα translation rates [93] or compounds that inhibit major signaling pathways such as sora…”
BackgroundMgcRacGAP Interacts with HIF-1α and Regulates its Transcriptional Activity
Lyberopoulou, A., Venieris, E., Mylonis, I., Chachami, G., Pappas, I., Simos, G., Bonanou, S., & Georgatsou, E. (2007) · Cellular Physiology and Biochemistry · doi:10.1159/000110460 · Cited by 36 · cited 1×
“Regulation of the HIF-1 heterodimer assembly by phosphorylation as well as by MgcRacGAP [46,47] highlights the HIF-1α/ARNT interaction as a target for peptide inhibitors modelled after the PAS domain, an approach that has indeed been successfully tried (see also below).”
BackgroundSelf-citationAlbanese, A., Daly, L. A., Mennerich, D., et al. (2020) · Preprints.org · doi:10.20944/preprints202012.0112.v1 · Cited by 33
Gkotinakou, I., Kechagia, E., Pazaitou‐Panayiotou, K., Mylonis, I., Liakos, P., & Tsakalof, A. K. (2020) · Cells · doi:10.3390/cells9112440 · Cited by 31 · cited 1×
“, rapamycin) [109], steroids such as calcitriol that influence HIFα translation rates [93] or compounds that inhibit major signaling pathways such as sorafenib [94] or YC-1 [95].”
BackgroundSelf-citationPharmacological HIF-inhibition attenuates postoperative adhesion formation
Strowitzki, M. J., Ritter, A. S., Radhakrishnan, P., Harnoss, J. M., Opitz, V. M., Biller, M., Wehrmann, J., Keppler, U., Scheer, J., Wallwiener, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13638-z · Cited by 30
Mistry, I. N., & Tavassoli, A. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.6b00219 · Cited by 28
Lyberopoulou, A., Mylonis, I., Papachristos, G., Sagris, D., Kalousi, A., Befani, C. D., Liakos, P., Simos, G., & Georgatsou, E. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.02.025 · Cited by 15 · cited 1×
“Regulation of the HIF-1 heterodimer assembly by phosphorylation as well as by MgcRacGAP [46,47] highlights the HIF-1α/ARNT interaction as a target for peptide inhibitors modelled after the PAS domain, an approach that has indeed been successfully tried (see also below).”
BackgroundSelf-citationHetherington, K., Hegedüs, Z., Edwards, T. A., Sessions, R. B., Nelson, A. S., & Wilson, A. J. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202000417 · Cited by 15
Wang, Y., Thompson, J., & Chan, W. K. (2013) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2013.02.003 · Cited by 9
Wang, Y., Li, Y., Wang, D., Li, Y., Chang, A. B., & Chan, W. K. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.037 · Cited by 8
HIF-1α ODD polypeptides increased the expression of HIF1 and VEGF in hypoxic rat cortical neuron
Liu, X., Du, J., & Xi, Q. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0574-8 · Cited by 7
Cited by
Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target
Infantino, V., Santarsiero, A., Convertini, P., Todisco, S., & Iacobazzi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115703 · Cited by 499
Functions of the aryl hydrocarbon receptor (AHR) beyond the canonical AHR/ARNT signaling pathway
Sondermann, N. C., Faßbender, S., Hartung, F., Hätälä, A. M., Rolfes, K. M., Vogel, C. F. A., & Haarmann-Stemmann, T. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115371 · Cited by 181
The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
Basheeruddin, M., & Qausain, S. (2024) · Cureus · doi:10.7759/cureus.70700 · Cited by 299
Shaikat, A. H., Azad, S. M. A. K., Tamim, M. A. R., Ullah, M. S., Amin, M. N., Sabbir, M. K., Tarun, M. T. I., Mostaq, M. S., Sabrin, S., Mahmud, M. Z., et al. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.07.003 · Cited by 44
Metadata
- Authors
- Mylonis, I., Chachami, G., & Simos, G.
- Affiliations
- University of Thessaly (GR)
- Corresponding author
- Mylonis, Ilias
- Simos, George
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-01-22
- Volume
- 13
- Issue
- 3
- Pages
- 410
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC7865418
- OpenAlex
- W3123050006
- Cited by
- 21
- References
- 140
- Citations by year
- 2025: 4 · 2024: 6 · 2023: 4 · 2022: 4 · 2021: 3
- FWCI
- 0.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- University of Thessaly Institutional Repository (University of Thessaly) (submittedVersion)
- Funders
- Fondation Santé (5360)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Kruppel-like factors research
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Keywords
- hypoxia-inducible factor, HIF inhibitors, peptide inhibitors, protein-protein interaction, transcription factor targeting, angiogenesis, erythropoiesis, HIF-targeted therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.